Novartis | NOVN - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
AbbVie USD -6.66B 3.39B 2026-03
Alcon AG USD 22.13B 99M 2026-03
Almirall EUR 1.49B 24.03M 2025-12
Amgen USD 9.19B 532M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
Autolus Therapeutics Ltd USD 108.83M 69.3M 2026-03
Bayer EUR 28.85B 2.9B 2026-03
Biogen USD 18.65B 394.9M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Fresenius EUR 19.77B 1.14B 2025-12
Fresenius Medical Care EUR 14.2B 13.95B 2026-03
Genmab DKK 5.85B 96M 2025-12
Gilead Sciences USD 23.52B 897M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
GRIFOLS EUR 5.46B 171M 2026-03
Hikma Pharmaceutical USD 2.59B 42M 2025-12
J&J USD 81.19B 358M 2026-03
Lakefront Biotherapeutics EUR 3.25B 17.5M 2026-03
Lonza CHF 9.13B 513M 2025-12
Merck EUR 29.74B 1.15B 2026-03
Merck USD 45.88B 6.73B 2026-03
Novartis USD 38.93B 7.2B 2026-03
Novartis USD 38.93B 7.2B 2026-03
Novo Nordisk DKK 203.07B 9.02B 2026-03
Orion EUR 1.12B 162.1M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Philips EUR 11.39B 403M 2026-03
Recordati EUR 2.06B 140.52M 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sanofi EUR 72.81B 1.1B 2026-03
UCB EUR 10.87B 1.18B 2025-12